The phase II KEYNOTE-199 study included three cohorts of patients with mCRPC treated with docetaxel and one or more targeted endocrine therapies. Cohorts 1 and 2 enrolled patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback